AbbVie closes in on Biohaven with new migraine prevention OK for oral CGRP drug

You can now add a hefty pharma player to the commercial battle for migraine prevention.

AbbVie has landed an approval for Qulipta, the oral CGRP receptor antagonist it obtained via the $63 billion buyout of Allergan and the third FDA-approved drug in its migraine portfolio.

While AbbVie’s other CGRP...

Click to view original post